Please use this identifier to cite or link to this item:
Title: Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma
Authors: Baiocchi, Otavio Carvalho Guimarães [UNIFESP]
Colleoni, Gisele Wally Braga [UNIFESP]
Navajas, Eduardo Vitor [UNIFESP]
Duarte, Luiz Cláudio de Carvalho [UNIFESP]
Alves, Antonio Correa [UNIFESP]
Andrade, Ana Lúcia Sampaio Sgambatti de
Kerbauy, José [UNIFESP]
Oliveira, José Salvador Rodrigues de [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
Universidade Federal de Goiás (UFG)
Issue Date: 1-Apr-2002
Publisher: Taylor & Francis As
Citation: Acta Oncologica. Oslo: Taylor & Francis As, v. 41, n. 2, p. 192-196, 2002.
Abstract: Twenty cases of systemic non-Hodgkin's lymphoma (NHL) in HIV-infected patients were reviewed over a 10-year-period, divided into Group A, including 13 NHL cases treated before the highly active antiretroviral therapy (HAART) era, and Group B, including 7 patients who received HAART. A Kaplan-Meier survival curve was performed and log-rank was applied to assess statistical differences between the groups. In group A, the median CD4 count was 36 cells/mm(3). No complete remission was found. In group B, the median CD4 count was 137 cells/mm(3). Four patients (57.0%) are still alive and in complete remission. Group A had a median survival of 5 months and group B 31 months (p = 0.0032). Our results are in agreement with recent reports in that a higher CD4 count and better immune status achieved with HAART is predictive of a better outcome. We found that HAART in combination with chemotherapy improves overall survival of NHL patients without increasing adverse effects.
ISSN: 0284-186X
Other Identifiers:
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.